19 June 2017 - The EMA has published a draft agenda for this week's CHMP meeting.

ThE CHMP is due to issue initial opinions for the following technologies:

• Tenofovir disoproxil fumarate with emtricitabine and efavirenz
  
• Tivozanib hydrochloride monohydrate
  
• Adalimumab
  
• Alfa-1-anti-trypsin (human)
  
• Ribociclib succinate
  
• Cladribine
  
• Glecaprevir with pibrentasvir
  
• Nitisinone
  
• Midostaurin
  
• Sofosbuvir with velpatasvir and voxilaprevir
  

Read CHMP agenda